POM-V
Prescription Required
Companion Animal
Suprelorin 4.7 mg Implant for Dogs and Cats
Active ingredient: Deslorelin
Form
Implant
Species
Cats
Dogs
Manufacturer
VIRBAC
VMD MA No.
05653/5017
What it's used for
Male dog: For the induction of temporary infertility in healthy, intact, sexually mature male dogs. Prepubertal female dog: For the induction of temporary...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Deslorelin
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Suprelorin 4.7 mg Implant for Dogs and Cats — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.
Male dog:
For the induction of temporary infertility in healthy, intact, sexually mature male dogs.
Prepubertal female dog:
For the induction of temporary infertility to delay the first oestrus and heat signs, and
to prevent pregnancy at a young age in intact and healthy sexually immature female
dogs. The implant should be administered between 12 and 16 weeks of age.
Male cat:
For the induction of temporary infertility and suppression of urine odour and of sexual
behaviours such as libido, vocalisation, urine marking, and aggressiveness in intact
male cats from 3 months of age.
For the induction of temporary infertility in healthy, intact, sexually mature male dogs.
Prepubertal female dog:
For the induction of temporary infertility to delay the first oestrus and heat signs, and
to prevent pregnancy at a young age in intact and healthy sexually immature female
dogs. The implant should be administered between 12 and 16 weeks of age.
Male cat:
For the induction of temporary infertility and suppression of urine odour and of sexual
behaviours such as libido, vocalisation, urine marking, and aggressiveness in intact
male cats from 3 months of age.
Subcutaneous use.
The recommended dose is one implant per dog or cat, irrespective of the size of the
dog or the cat (see also point 4.4).
Disinfection of the implantation site should be undertaken prior to implantation to avoid
introduction of infection. If the hair is long, a small area should be clipped, if required.
The veterinary medicinal product should be implanted subcutaneously under the loose
skin on the back between the lower neck and the lumbar area. Avoid injection of the
implant into fat, as release of the active substance might be impaired in areas of low
vascularisation.
1. Remove Luer Lock cap from the implanter.
2. Attach the actuator to the implanter using the Luer Lock connection.
3. Lift the loose skin between the shoulder blades. Insert the entire length of the needle
subcutaneously.
4. Fully depress the actuator plunger and, at the same time, slowly withdraw the
needle.
5. Press the skin at the insertion site as the needle is withdrawn, and maintain pressure
for 30 seconds.
6. Examine the syringe and needle to ensure that the implant has not remained within
the syringe or needle, and that the spacer is visible. It may be possible to palpate the
implant in situ.
Revised: March 2026
AN: 03554/2025
Repeat administration every 6 months to maintain efficacy in male dogs and every 12
months to maintain efficacy in male cats.
Do not use the veterinary medicinal product if the foil pouch is broken.
The implant is biocompatible and does not require removal. However, should it be
necessary to end treatment, the implant or its fragments may be surgically removed
by a veterinarian. Implants may be located using ultrasound.
The recommended dose is one implant per dog or cat, irrespective of the size of the
dog or the cat (see also point 4.4).
Disinfection of the implantation site should be undertaken prior to implantation to avoid
introduction of infection. If the hair is long, a small area should be clipped, if required.
The veterinary medicinal product should be implanted subcutaneously under the loose
skin on the back between the lower neck and the lumbar area. Avoid injection of the
implant into fat, as release of the active substance might be impaired in areas of low
vascularisation.
1. Remove Luer Lock cap from the implanter.
2. Attach the actuator to the implanter using the Luer Lock connection.
3. Lift the loose skin between the shoulder blades. Insert the entire length of the needle
subcutaneously.
4. Fully depress the actuator plunger and, at the same time, slowly withdraw the
needle.
5. Press the skin at the insertion site as the needle is withdrawn, and maintain pressure
for 30 seconds.
6. Examine the syringe and needle to ensure that the implant has not remained within
the syringe or needle, and that the spacer is visible. It may be possible to palpate the
implant in situ.
Revised: March 2026
AN: 03554/2025
Repeat administration every 6 months to maintain efficacy in male dogs and every 12
months to maintain efficacy in male cats.
Do not use the veterinary medicinal product if the foil pouch is broken.
The implant is biocompatible and does not require removal. However, should it be
necessary to end treatment, the implant or its fragments may be surgically removed
by a veterinarian. Implants may be located using ultrasound.
None.
All target species:
Prepubertal surgical gonadectomy as well as prepubertal hormonal suppression may
delay physeal closure in long-bones, typically without clinical or pathological
consequences.
Dog (male and female):
Moderate swelling or scabbing at the implant site was commonly observed for 14 days
during safety/efficacy studies. Local dermatitis lasting up to 6 months was commonly
reported in a field trial.
During the treatment period, rare clinical effects have been reported:
Hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence,
down-regulation associated signs (e.g. decrease in testicle size, reduced activity,
weight gain) have been reported rarely during the treatment period.
A testicle may be able to ascend up through the inguinal ring , in very rare cases.
Transitory increased sexual interest, increased testicle size and testicular pain
immediately following implantation were reported very rarely. These signs resolved
without treatment.
Transient behavioural change with the development of aggression have been
reported very rarely (see section 4.4).
In humans and animals, sexual hormones (testosterone and progesterone) modulate
seizure susceptibility. Epileptic seizures have been observed very rarely and have
been reported on average 40 days after implantation, the median time to onset of
signs was 14 days after implantation, on the same
day of implantation at the earliest, and 36 weeks after implantation at the latest.
Cat:
Local reactions consisting of redness and pain or heat on the day of implantation,
that were transient, were commonly observed. Swellings (<5mm) were commonly
seen for up to 45 days, in a field study. Severe swelling (>4 cm) lasting for more than
7 months was reported in 1 out 18 cats in a laboratory study.
Increased sexual activity and roaming may be observed transiently in mature male
cats during the first weeks post implantation
Revised: March 2026
AN: 03554/2025
Increased food intake and increase of body weight are known to be associated with
neutering. Some treated cats increase their body weight up to 10% during the period
of effect.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Prepubertal surgical gonadectomy as well as prepubertal hormonal suppression may
delay physeal closure in long-bones, typically without clinical or pathological
consequences.
Dog (male and female):
Moderate swelling or scabbing at the implant site was commonly observed for 14 days
during safety/efficacy studies. Local dermatitis lasting up to 6 months was commonly
reported in a field trial.
During the treatment period, rare clinical effects have been reported:
Hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence,
down-regulation associated signs (e.g. decrease in testicle size, reduced activity,
weight gain) have been reported rarely during the treatment period.
A testicle may be able to ascend up through the inguinal ring , in very rare cases.
Transitory increased sexual interest, increased testicle size and testicular pain
immediately following implantation were reported very rarely. These signs resolved
without treatment.
Transient behavioural change with the development of aggression have been
reported very rarely (see section 4.4).
In humans and animals, sexual hormones (testosterone and progesterone) modulate
seizure susceptibility. Epileptic seizures have been observed very rarely and have
been reported on average 40 days after implantation, the median time to onset of
signs was 14 days after implantation, on the same
day of implantation at the earliest, and 36 weeks after implantation at the latest.
Cat:
Local reactions consisting of redness and pain or heat on the day of implantation,
that were transient, were commonly observed. Swellings (<5mm) were commonly
seen for up to 45 days, in a field study. Severe swelling (>4 cm) lasting for more than
7 months was reported in 1 out 18 cats in a laboratory study.
Increased sexual activity and roaming may be observed transiently in mature male
cats during the first weeks post implantation
Revised: March 2026
AN: 03554/2025
Increased food intake and increase of body weight are known to be associated with
neutering. Some treated cats increase their body weight up to 10% during the period
of effect.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
All target species:
In certain cases, the implant may be lost from a treated animal. If lack of expected
efficacy is suspected, then the subcutaneous presence of the implant should be
checked.
Revised: March 2026
AN: 03554/2025
Male dog:
Infertility is achieved from 6 weeks up to at least 6 months after initial treatment.
Treated dogs should therefore still be kept away from bitches on heat within the first
6 weeks after initial treatment.
One out of 75 dogs treated with the veterinary medicinal product during clinical trials
mated and tied with a bitch on heat within six months of implantation, but this did not
result in pregnancy. Should a treated dog mate with a bitch between 6 weeks and 6
months after treatment, appropriate measures should be taken to rule out the risk of
pregnancy.
In rare cases, suspected lack of expected efficacy has been reported (in the majority
of cases a lack of reduction of testicle size was reported and/or a bitch was mated).
Only testosterone levels (i.e. an established surrogate marker of fertility) could
definitely confirm a lack of efficacy of the treatment.
Any mating that occurs more than 6 months after the administration of the veterinary
medicinal product may result in pregnancy. However, it is not necessary to keep
bitches away from treated dogs following subsequent implantations, provided that the
veterinary medicinal product is administered every 6 months.
If loss of the first implant is suspected, then this can be confirmed by observing no
reduction in scrotal circumference or plasma testosterone levels after 6 weeks from
the suspected date of loss, as both should reduce under correct implantation. If loss
of the implant is suspected following re-implantation after 6 months, then a
progressive increase will be seen in scrotal circumference and/or plasma
testosterone levels. In both of these circumstances a replacement implant should be
administered.
The ability of dogs to sire offspring following their return to normal plasma
testosterone levels, after the administration of the veterinary medicinal product, has
not been investigated.
With respect to testosterone levels (an established surrogate marker of fertility),
during clinical trials more than 80 % of dogs administered one or more implants,
returned to normal plasma testosterone levels (≥0.4 ng/ml) within 12 months of
implantation. Ninety-eight percent of dogs returned to normal plasma testosterone
levels within 18 months of implantation. However, data demonstrating the complete
reversibility of clinical effects (reduced testicular size, reduced ejaculation volume,
reduced sperm count and reduced libido) including fertility after 6 months, or
repeated implantation, are limited. In very rare cases, the temporary infertility may
last more than 18 months.
During clinical trials, most of the smaller size dogs (<10 kg bodyweight) maintained
suppressed levels of testosterone for more than 12 months following implantation.
For very large dogs (>40 kg bodyweight), data are limited but duration of testosterone
suppression was comparable to that seen in medium and large dogs. The use of the
veterinary medicinal product in dogs of less than 10 kg or more than 40 kg
bodyweight, therefore, should be subject to a risk/benefit assessment performed by
the veterinarian.
Revised: March 2026
AN: 03554/2025
Surgical or medical castration might have unexpected consequences (i.e.
improvement or worsening) on aggressive behaviour. Thus, dogs with sociopathic
disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific
(dog to another species) aggressions should not be castrated either surgically or with
the implant.
Prepubertal female dog:
During clinical trials, the first oestrus occured 6 to 24 months after administration of
the product in 98.2% of animals; for one out of 56 female dogs (1.8%) suppression of
oestrus lasted 5 months. Specifically, 44.6% of female dogs displayed their first
oestrus between 6 and 12 months post-implantation, 53.6% between 12 and 24
months post-implantation.
The veterinary medicinal product should only be administered to prepubertal bitches
aged 12-16 weeks, which do not display any signs of oestrus. Measurements of
hormonal levels and vaginal smears can be used to confirm the absence of oestrus
Male cat:
In mature male cats, induction of infertility and suppression of urine odour and sexual
behaviours are achieved from approximately 6 weeks up to 12 months after
implantation. Should a male cat mate with a queen before 6 weeks or after 12
months of being implanted, appropriate measures should be taken to rule out the risk
of pregnancy.
When implanted in 3-month old male kittens, suppression of fertility lasted at least for
12 months in 100% of cats and for more than 16 months in 20% of cats.
For most cats, within 2 weeks after implantation, testosterone levels drop, followed
by reduced testicular volume and reduced size of penile spines from weeks 4-8 after
implantation. Sexual behaviours begin to decrease within a week after treatment,
starting with reduced vocalisation, followed by reduction in libido, urine odour, urine
marking, and aggressiveness from 4 weeks after implantation. Some sexual
behaviours, e.g., mounting and neck-biting, may also have a social component,
however, the downregulated male cat cannot complete a mating or induce ovulation
in the queen. Clinical effects on urine odour, urine marking, testicular volume, penile
spine size, and sexual behaviours begin to wane after approximately 12 months post
implantation.
The time-course and duration of down-regulation observed after treatment is variable
with 28 months being the maximum duration observed to return to normal fertility
following implantation.
In a field study, 22 male cats were administered a second implant 12 months after
the first one which extended the duration of suppressed reproductive function and
sexual behaviours for another year.
In 1-3% of male cats, lack of expected efficacy has been reported based on
continued expression of sexual behaviours, mating resulting in pregnancy, and/or
lack of suppression of plasma testosterone levels (an established surrogate marker
of fertility). In case of doubt, the animal owner should consider keeping the treated
tomcat separate from queens where pregnancy would be undesirable.
Revised: March 2026
AN: 03554/2025
Special precautions for use in animals
Male dog:
The use of the veterinary medicinal product in pre-pubertal male dogs has not been
investigated. It is therefore recommended that male dogs should be allowed to reach
puberty before treatment with the veterinary medicinal product is initiated.
Data demonstrate that treatment with the veterinary medicinal product will reduce the
libido of the male dog.
Prepubertal female dog:
In a study, out of the 34 female dogs that were implanted between 16 and 18 weeks
of age, one animal implanted at 16 to 17 weeks of age and two animals implanted at
17 to 18 weeks of age displayed an implant-induced oestrus.
Repeated treatment has not been investigated in female dogs and is, therefore, not
recommended.
After reaching sexual maturity following the end of the effect of one implant,
information has been collected about heat cycles and the ability of female dogs to
produce litters: no reproductive safety concerns were noticed. In a follow-up survey
six pregnancies in five bitches were completed with one to nine alive puppies. Due to
the limited amount of data, the use in prepubertal female dogs intended for breeding
should be made according to a benefit/risk assessment by the responsible
veterinarian.
The use in sexually mature female dogs to supress reproductive function and oestrus
cycling is not recommended, due to the risk of inducing an oestrus, which may cause
uterine and ovarian pathology (metropathy, cysts) and unwanted pregnancy.
Male cat:
No data is available in kittens with undescended testicles at implantation. It is
recommended to wait until the testicles have descended before administering the
product.
Limited data is available regarding return to normal fertility after repeated
administrations of the veterinary medicinal product.
The ability of cats to sire offspring following their return to normal plasma
testosterone levels, after the administration of the veterinary medicinal product, has
not been fully demonstrated, especially in prepubertal cats. A decision to use the
veterinary medicinal product in male cats that are intended to be used for breeding
therefore needs to be made on a case by case basis.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Pregnant women should not administer the veterinary medicinal product. Another
GnRH analogue has been shown to be foetotoxic in laboratory animals. Specific
studies to evaluate the effect of deslorelin when administered during pregnancy have
not been conducted.
Revised: March 2026
AN: 03554/2025
Although skin contact with the veterinary medicinal product is unlikely, should this
occur, wash the exposed area immediately, as GnRH analogues may be absorbed
through the skin.
When administering the veterinary medicinal product, take care to avoid accidental
self-injection by ensuring that animals are suitably restrained and the application
needle is shielded until the moment of implantation.
In case of accidental self-injection, seek medical advice immediately, with a view to
having the implant removed. Show the package leaflet or the label to the physician.
In certain cases, the implant may be lost from a treated animal. If lack of expected
efficacy is suspected, then the subcutaneous presence of the implant should be
checked.
Revised: March 2026
AN: 03554/2025
Male dog:
Infertility is achieved from 6 weeks up to at least 6 months after initial treatment.
Treated dogs should therefore still be kept away from bitches on heat within the first
6 weeks after initial treatment.
One out of 75 dogs treated with the veterinary medicinal product during clinical trials
mated and tied with a bitch on heat within six months of implantation, but this did not
result in pregnancy. Should a treated dog mate with a bitch between 6 weeks and 6
months after treatment, appropriate measures should be taken to rule out the risk of
pregnancy.
In rare cases, suspected lack of expected efficacy has been reported (in the majority
of cases a lack of reduction of testicle size was reported and/or a bitch was mated).
Only testosterone levels (i.e. an established surrogate marker of fertility) could
definitely confirm a lack of efficacy of the treatment.
Any mating that occurs more than 6 months after the administration of the veterinary
medicinal product may result in pregnancy. However, it is not necessary to keep
bitches away from treated dogs following subsequent implantations, provided that the
veterinary medicinal product is administered every 6 months.
If loss of the first implant is suspected, then this can be confirmed by observing no
reduction in scrotal circumference or plasma testosterone levels after 6 weeks from
the suspected date of loss, as both should reduce under correct implantation. If loss
of the implant is suspected following re-implantation after 6 months, then a
progressive increase will be seen in scrotal circumference and/or plasma
testosterone levels. In both of these circumstances a replacement implant should be
administered.
The ability of dogs to sire offspring following their return to normal plasma
testosterone levels, after the administration of the veterinary medicinal product, has
not been investigated.
With respect to testosterone levels (an established surrogate marker of fertility),
during clinical trials more than 80 % of dogs administered one or more implants,
returned to normal plasma testosterone levels (≥0.4 ng/ml) within 12 months of
implantation. Ninety-eight percent of dogs returned to normal plasma testosterone
levels within 18 months of implantation. However, data demonstrating the complete
reversibility of clinical effects (reduced testicular size, reduced ejaculation volume,
reduced sperm count and reduced libido) including fertility after 6 months, or
repeated implantation, are limited. In very rare cases, the temporary infertility may
last more than 18 months.
During clinical trials, most of the smaller size dogs (<10 kg bodyweight) maintained
suppressed levels of testosterone for more than 12 months following implantation.
For very large dogs (>40 kg bodyweight), data are limited but duration of testosterone
suppression was comparable to that seen in medium and large dogs. The use of the
veterinary medicinal product in dogs of less than 10 kg or more than 40 kg
bodyweight, therefore, should be subject to a risk/benefit assessment performed by
the veterinarian.
Revised: March 2026
AN: 03554/2025
Surgical or medical castration might have unexpected consequences (i.e.
improvement or worsening) on aggressive behaviour. Thus, dogs with sociopathic
disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific
(dog to another species) aggressions should not be castrated either surgically or with
the implant.
Prepubertal female dog:
During clinical trials, the first oestrus occured 6 to 24 months after administration of
the product in 98.2% of animals; for one out of 56 female dogs (1.8%) suppression of
oestrus lasted 5 months. Specifically, 44.6% of female dogs displayed their first
oestrus between 6 and 12 months post-implantation, 53.6% between 12 and 24
months post-implantation.
The veterinary medicinal product should only be administered to prepubertal bitches
aged 12-16 weeks, which do not display any signs of oestrus. Measurements of
hormonal levels and vaginal smears can be used to confirm the absence of oestrus
Male cat:
In mature male cats, induction of infertility and suppression of urine odour and sexual
behaviours are achieved from approximately 6 weeks up to 12 months after
implantation. Should a male cat mate with a queen before 6 weeks or after 12
months of being implanted, appropriate measures should be taken to rule out the risk
of pregnancy.
When implanted in 3-month old male kittens, suppression of fertility lasted at least for
12 months in 100% of cats and for more than 16 months in 20% of cats.
For most cats, within 2 weeks after implantation, testosterone levels drop, followed
by reduced testicular volume and reduced size of penile spines from weeks 4-8 after
implantation. Sexual behaviours begin to decrease within a week after treatment,
starting with reduced vocalisation, followed by reduction in libido, urine odour, urine
marking, and aggressiveness from 4 weeks after implantation. Some sexual
behaviours, e.g., mounting and neck-biting, may also have a social component,
however, the downregulated male cat cannot complete a mating or induce ovulation
in the queen. Clinical effects on urine odour, urine marking, testicular volume, penile
spine size, and sexual behaviours begin to wane after approximately 12 months post
implantation.
The time-course and duration of down-regulation observed after treatment is variable
with 28 months being the maximum duration observed to return to normal fertility
following implantation.
In a field study, 22 male cats were administered a second implant 12 months after
the first one which extended the duration of suppressed reproductive function and
sexual behaviours for another year.
In 1-3% of male cats, lack of expected efficacy has been reported based on
continued expression of sexual behaviours, mating resulting in pregnancy, and/or
lack of suppression of plasma testosterone levels (an established surrogate marker
of fertility). In case of doubt, the animal owner should consider keeping the treated
tomcat separate from queens where pregnancy would be undesirable.
Revised: March 2026
AN: 03554/2025
Special precautions for use in animals
Male dog:
The use of the veterinary medicinal product in pre-pubertal male dogs has not been
investigated. It is therefore recommended that male dogs should be allowed to reach
puberty before treatment with the veterinary medicinal product is initiated.
Data demonstrate that treatment with the veterinary medicinal product will reduce the
libido of the male dog.
Prepubertal female dog:
In a study, out of the 34 female dogs that were implanted between 16 and 18 weeks
of age, one animal implanted at 16 to 17 weeks of age and two animals implanted at
17 to 18 weeks of age displayed an implant-induced oestrus.
Repeated treatment has not been investigated in female dogs and is, therefore, not
recommended.
After reaching sexual maturity following the end of the effect of one implant,
information has been collected about heat cycles and the ability of female dogs to
produce litters: no reproductive safety concerns were noticed. In a follow-up survey
six pregnancies in five bitches were completed with one to nine alive puppies. Due to
the limited amount of data, the use in prepubertal female dogs intended for breeding
should be made according to a benefit/risk assessment by the responsible
veterinarian.
The use in sexually mature female dogs to supress reproductive function and oestrus
cycling is not recommended, due to the risk of inducing an oestrus, which may cause
uterine and ovarian pathology (metropathy, cysts) and unwanted pregnancy.
Male cat:
No data is available in kittens with undescended testicles at implantation. It is
recommended to wait until the testicles have descended before administering the
product.
Limited data is available regarding return to normal fertility after repeated
administrations of the veterinary medicinal product.
The ability of cats to sire offspring following their return to normal plasma
testosterone levels, after the administration of the veterinary medicinal product, has
not been fully demonstrated, especially in prepubertal cats. A decision to use the
veterinary medicinal product in male cats that are intended to be used for breeding
therefore needs to be made on a case by case basis.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Pregnant women should not administer the veterinary medicinal product. Another
GnRH analogue has been shown to be foetotoxic in laboratory animals. Specific
studies to evaluate the effect of deslorelin when administered during pregnancy have
not been conducted.
Revised: March 2026
AN: 03554/2025
Although skin contact with the veterinary medicinal product is unlikely, should this
occur, wash the exposed area immediately, as GnRH analogues may be absorbed
through the skin.
When administering the veterinary medicinal product, take care to avoid accidental
self-injection by ensuring that animals are suitably restrained and the application
needle is shielded until the moment of implantation.
In case of accidental self-injection, seek medical advice immediately, with a view to
having the implant removed. Show the package leaflet or the label to the physician.
None known.
Store in a refrigerator (2C – 8C).
Do not freeze.
Do not freeze.
for 30 seconds.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Same active ingredient
Other Products Containing Deslorelin
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in hormone
Related Medications
ACEGON 50 micrograms/ml Solution for Injection for Cattle
POM-VGonadorelin
injection
Rx
Cattle
Altresyn 4 mg/ml Oral Solution for Pigs
POM-VAltrenogest
liquid
Rx
Pigs
Altresyn 4 mg/ml Oral Solution for Pigs
POM-VAltrenogest
liquid
Rx
Pigs
Busol - 0.004 mg/ml Solution for Injection for Cattle, Horses, Rabbits
POM-VBuserelin
injection
Rx
Cattle
Horses
Caninsulin 40 IU/ml Suspension for Injection
POM-VInsulin
injection
Rx
Cats
Dogs
Chorulon 1500 IU Powder and Solvent for Solution for Injection
POM-VChorionic Gonadotrophin
injection
Rx
Cattle
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.